Luis F. Schachner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luis F. Schachner has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Neil L. Kelleher
Northwestern University
12 shared publications - Alexander S. Lee
Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, USA
4 shared publications - Michael-Christopher Keogh
EpiCypher Inc. , Durham, NC 27709
4 shared publications Sarah A. Howard
EpiCypher Inc., Durham, NC 27709
3 shared publicationsAlexander S. Lee
Departments of Chemistry and Molecular Biosciences, the Chemistry of Life Processes Institute, and the Proteomics Center of Excellence, Northwestern University, Evanston, IL 60208
2 shared publications- Ali Shilatifard
Simpson Querrey Center for Epigenetics, Northwestern University Feinberg School of Medicine
2 shared publications
Latest Publications
- 17 June 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2426-2437
Direct Quantification of Complement Biomarkers Using Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)
The classical complement pathway is a critical therapeutic target for numerous diseases, but the lack of robust, translatable biomarkers hinders drug development. Here, we report the development and qualification of a quantitative liquid chromatography-tandem mass spectrometry (LC–MS/MS) platform to measure key classical pathway proteins─C1q, C 1s (total and active), and the native C1q/C 1s complex. The platform was established across human, cynomolgus monkey, and mouse samples, including serum, plasma, cerebrospinal fluid, and brain homogenates. We employed two complementary workflows: an affinity capture LC–MS/MS method to quantify the intact C1q/C 1s complex and a direct digestion strategy to differentiate total C 1s from its active form. The assays met rigorous qualification standards for accuracy, reproducibility (CV ≤15%) and freeze–thaw stability. Applying this platform, we established that cynomolgus monkeys exhibit complement profiles highly similar to those in healthy humans, validating their use as a translational model. In contrast, mice display markedly higher baseline levels of active C 1s, revealing a critical species-specific difference in complement regulation. This qualified, cross-species platform provides an essential tool for bridging preclinical and clinical research and enabling reliable pharmacodynamic assessment of complement-targeting therapeutics.
- 17 June 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2426-2437
Direct Quantification of Complement Biomarkers Using Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)
The classical complement pathway is a critical therapeutic target for numerous diseases, but the lack of robust, translatable biomarkers hinders drug development. Here, we report the development and qualification of a quantitative liquid chromatography-tandem mass spectrometry (LC–MS/MS) platform to measure key classical pathway proteins─C1q, C 1s (total and active), and the native C1q/C 1s complex. The platform was established across human, cynomolgus monkey, and mouse samples, including serum, plasma, cerebrospinal fluid, and brain homogenates. We employed two complementary workflows: an affinity capture LC–MS/MS method to quantify the intact C1q/C 1s complex and a direct digestion strategy to differentiate total C 1s from its active form. The assays met rigorous qualification standards for accuracy, reproducibility (CV ≤15%) and freeze–thaw stability. Applying this platform, we established that cynomolgus monkeys exhibit complement profiles highly similar to those in healthy humans, validating their use as a translational model. In contrast, mice display markedly higher baseline levels of active C 1s, revealing a critical species-specific difference in complement regulation. This qualified, cross-species platform provides an essential tool for bridging preclinical and clinical research and enabling reliable pharmacodynamic assessment of complement-targeting therapeutics.
- Open Access
Direct Readout of Multivalent Chromatin Reader-Nucleosome Interactions by Nucleosome Mass Spectrometry
Histone post-translational modifications (PTMs) often serve as distinct recognition sites for the recruitment of chromatin-associated proteins (CAPs) for epigenome regulation. While CAP-PTM interactions have been extensively studied using histone peptides, this cannot consider the regulatory potential of multi-site binding on intact nucleosomes. To overcome this limitation, we applied Nucleosome Mass Spectrometry (Nuc-MS), a native Top-Down MS approach that enables controlled disassembly of intact CAP:nucleosome (CAP:nuc) complexes to provide a direct readout of the contained histone proteoforms. As proof of principle, we show the BPTF PHD-BD native tandem reader requires coincident H3K4me3K9acK14acK18ac for effective nucleosome engagement. We extend our approach to explore how the BRD4 (native BD1-BD2), DNMT3A-MPP8 (chimeric PWWP-CD), and PtSHL (native BAH-BD) tandem readers interact with endogenous nucleosomes. Each reveals distinct enrichment profiles: BRD4 favoring di- and tri-acetylated histone H4 proteoforms, whereas DNMT3A-MPP8 and PtSHL preferentially interact with hypermethylated H3 proteoforms. Of note the latter enriches combinatorial {H3K4me3K27me3} on the same histone tail in HeLa chromatin, and thus expands the potential biology of this widely studied bivalent signature. By directly characterizing CAP:nuc complex composition with combinatorial PTM information in a single readout, Nuc-MS serves as a new approach to discover the modifications driving binding, and therefore primary candidates to explore for structural biology and genomic studies. Abstract Figure: For TOC only. Synopsis.: Nuc-MS provides the ability to control the disassembly of chromatin-associated protein-nucleosome complexes (CAP-nuc) and delineate the histone proteoforms driving tandem reader domain binding.
Open AccessDirect Readout of Multivalent Chromatin Reader-Nucleosome Interactions by Nucleosome Mass Spectrometry
Histone post-translational modifications (PTMs) often serve as distinct recognition sites for the recruitment of chromatin-associated proteins (CAPs) for epigenome regulation. While CAP-PTM interactions have been extensively studied using histone peptides, this cannot consider the regulatory potential of multi-site binding on intact nucleosomes. To overcome this limitation, we applied Nucleosome Mass Spectrometry (Nuc-MS), a native Top-Down MS approach that enables controlled disassembly of intact CAP:nucleosome (CAP:nuc) complexes to provide a direct readout of the contained histone proteoforms. As proof of principle, we show the BPTF PHD-BD native tandem reader requires coincident H3K4me3K9acK14acK18ac for effective nucleosome engagement. We extend our approach to explore how the BRD4 (native BD1-BD2), DNMT3A-MPP8 (chimeric PWWP-CD), and PtSHL (native BAH-BD) tandem readers interact with endogenous nucleosomes. Each reveals distinct enrichment profiles: BRD4 favoring di- and tri-acetylated histone H4 proteoforms, whereas DNMT3A-MPP8 and PtSHL preferentially interact with hypermethylated H3 proteoforms. Of note the latter enriches combinatorial {H3K4me3K27me3} on the same histone tail in HeLa chromatin, and thus expands the potential biology of this widely studied bivalent signature. By directly characterizing CAP:nuc complex composition with combinatorial PTM information in a single readout, Nuc-MS serves as a new approach to discover the modifications driving binding, and therefore primary candidates to explore for structural biology and genomic studies. Abstract Figure: For TOC only. Synopsis.: Nuc-MS provides the ability to control the disassembly of chromatin-associated protein-nucleosome complexes (CAP-nuc) and delineate the histone proteoforms driving tandem reader domain binding.
- Open Access
Nucleosome context regulates chromatin reader preference
Chromatin is more than a simple genome packaging system, and instead locally distinguished by histone post-translational modifications (PTMs) that can directly change nucleosome structure and / or be “read” by chromatin-associated proteins to mediate downstream events. An accurate understanding of histone PTM binding preference is vital to explain normal function and pathogenesis, and has revealed multiple therapeutic opportunities. Such studies most often use histone peptides, even though these cannot represent the full regulatory potential of nucleosome context. Here we apply a range of complementary and easily adoptable biochemical and genomic approaches to interrogate fully defined peptide and nucleosome targets with a diversity of mono or multivalent chromatin readers. In the resulting data, nucleosome context consistently refined reader binding, and multivalent engagement was more often regulatory than simply additive. This included abrogating the binding of the Polycomb group L3MBTL1 MBT to histone tails with lower methyl states (me1 or me2 at H3K4, H3K9, H3K27, H3K36 or H4K20); and confirmation that the CBX7 chromodomain and AT-hook-like motif (CD-ATL) tandem act as a functional unit to confer specificity for H3K27me3. Further, in vitro nucleosome preferences were confirmed by in vivo reader-CUT&RUN genomic mapping. Such data confirms that more representative chromatin substrates provide greater insight to biological mechanism and its disorder in human disease.
Open AccessNucleosome context regulates chromatin reader preference
Chromatin is more than a simple genome packaging system, and instead locally distinguished by histone post-translational modifications (PTMs) that can directly change nucleosome structure and / or be “read” by chromatin-associated proteins to mediate downstream events. An accurate understanding of histone PTM binding preference is vital to explain normal function and pathogenesis, and has revealed multiple therapeutic opportunities. Such studies most often use histone peptides, even though these cannot represent the full regulatory potential of nucleosome context. Here we apply a range of complementary and easily adoptable biochemical and genomic approaches to interrogate fully defined peptide and nucleosome targets with a diversity of mono or multivalent chromatin readers. In the resulting data, nucleosome context consistently refined reader binding, and multivalent engagement was more often regulatory than simply additive. This included abrogating the binding of the Polycomb group L3MBTL1 MBT to histone tails with lower methyl states (me1 or me2 at H3K4, H3K9, H3K27, H3K36 or H4K20); and confirmation that the CBX7 chromodomain and AT-hook-like motif (CD-ATL) tandem act as a functional unit to confer specificity for H3K27me3. Further, in vitro nucleosome preferences were confirmed by in vivo reader-CUT&RUN genomic mapping. Such data confirms that more representative chromatin substrates provide greater insight to biological mechanism and its disorder in human disease.
- Open Access
Exposing the molecular heterogeneity of glycosylated biotherapeutics
Glycosylated biotherapeutics are an emerging class of drugs with high molecular heterogeneity, which can affect their safety and efficacy. Characterizing this heterogeneity is crucial for drug development and quality assessment, but existing methods are limited in their ability to analyze intact glycoproteins. Here, we present a new approach to glycoform fingerprinting that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact glycoproteins by mass spectrometry. The method provides a detailed landscape of the intact molecular weights present in biotherapeutic protein preparations in a single experiment and offers insights into glycoform composition when coupled with a suitable bioinformatic strategy. We tested the approach on various biotherapeutic molecules, including Fc-fusion, VHH-fusion, and peptide-bound MHC class II complexes to demonstrate efficacy in measuring the proteoform-level diversity of biotherapeutics. Notably, we inferred the glycoform distribution for hundreds of molecular weights for the eight-times glycosylated fusion drug IL22-Fc, enabling correlations between glycoform sub-populations and the drug’s pharmacological properties. Our method is broadly applicable and provides a powerful tool to assess the molecular heterogeneity of emerging biotherapeutics.
Open AccessExposing the molecular heterogeneity of glycosylated biotherapeutics
Glycosylated biotherapeutics are an emerging class of drugs with high molecular heterogeneity, which can affect their safety and efficacy. Characterizing this heterogeneity is crucial for drug development and quality assessment, but existing methods are limited in their ability to analyze intact glycoproteins. Here, we present a new approach to glycoform fingerprinting that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact glycoproteins by mass spectrometry. The method provides a detailed landscape of the intact molecular weights present in biotherapeutic protein preparations in a single experiment and offers insights into glycoform composition when coupled with a suitable bioinformatic strategy. We tested the approach on various biotherapeutic molecules, including Fc-fusion, VHH-fusion, and peptide-bound MHC class II complexes to demonstrate efficacy in measuring the proteoform-level diversity of biotherapeutics. Notably, we inferred the glycoform distribution for hundreds of molecular weights for the eight-times glycosylated fusion drug IL22-Fc, enabling correlations between glycoform sub-populations and the drug’s pharmacological properties. Our method is broadly applicable and provides a powerful tool to assess the molecular heterogeneity of emerging biotherapeutics.
- Open Access
- 30 September 2022
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 94 (42) , 14593-14602
High-Throughput, Quantitative Analysis of Peptide-Exchanged MHCI Complexes by Native Mass Spectrometry
Immune monitoring in cancer immunotherapy involves screening CD8+ T-cell responses against neoantigens, the tumor-specific peptides presented by Major histocompatibility complex Class I (MHCI) on the cell surface. High-throughput immune monitoring requires methods to produce and characterize small quantities of thousands of MHCI-peptide complexes that may be tested for a patient's T-cell response. MHCI synthesis has been achieved using a photocleavable peptide that is exchanged by the neoantigen; however, assays that measure peptide exchange currently disassemble the complex prior to analysis─precluding direct molecular characterization. Here, we use native mass spectrometry (MS) to profile intact recombinant MHCI complexes and directly measure peptide exchange. Coupled with size-exclusion chromatography or capillary-zone electrophoresis, the assay identified all tested human leukocyte antigen (HLA)/peptide combinations in the nanomole to picomole range with minimal run time, reconciling the synthetic and analytical requirements of MHCI-peptide screening with the downstream T-cell assays. We further show that the assay can be "multiplexed" by measuring exchange of multiple peptides simultaneously and also enables calculation of Vc50, a measure of gas-phase stability. Additionally, MHCI complexes were fragmented by top-down sequencing, demonstrating that the intact complex, peptide sequence, and their binding affinity can be determined in a single analysis. This screening tool for MHCI-neoantigen complexes represents a step toward the application of state-of-the-art MS technology in translational settings. Not only is this assay already informing on the viability of immunotherapy in practice, the platform also holds promise to inspire novel MS readouts for increasingly complex biomolecules used in the diagnosis and treatment of disease.
- 30 September 2022
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 94 (42) , 14593-14602
Open AccessHigh-Throughput, Quantitative Analysis of Peptide-Exchanged MHCI Complexes by Native Mass Spectrometry
Immune monitoring in cancer immunotherapy involves screening CD8+ T-cell responses against neoantigens, the tumor-specific peptides presented by Major histocompatibility complex Class I (MHCI) on the cell surface. High-throughput immune monitoring requires methods to produce and characterize small quantities of thousands of MHCI-peptide complexes that may be tested for a patient's T-cell response. MHCI synthesis has been achieved using a photocleavable peptide that is exchanged by the neoantigen; however, assays that measure peptide exchange currently disassemble the complex prior to analysis─precluding direct molecular characterization. Here, we use native mass spectrometry (MS) to profile intact recombinant MHCI complexes and directly measure peptide exchange. Coupled with size-exclusion chromatography or capillary-zone electrophoresis, the assay identified all tested human leukocyte antigen (HLA)/peptide combinations in the nanomole to picomole range with minimal run time, reconciling the synthetic and analytical requirements of MHCI-peptide screening with the downstream T-cell assays. We further show that the assay can be "multiplexed" by measuring exchange of multiple peptides simultaneously and also enables calculation of Vc50, a measure of gas-phase stability. Additionally, MHCI complexes were fragmented by top-down sequencing, demonstrating that the intact complex, peptide sequence, and their binding affinity can be determined in a single analysis. This screening tool for MHCI-neoantigen complexes represents a step toward the application of state-of-the-art MS technology in translational settings. Not only is this assay already informing on the viability of immunotherapy in practice, the platform also holds promise to inspire novel MS readouts for increasingly complex biomolecules used in the diagnosis and treatment of disease.
- 11 August 2022
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 17 (10) , 2769-2780
Revving an Engine of Human Metabolism: Activity Enhancement of Triosephosphate Isomerase via Hemi-Phosphorylation
Triosephosphate isomerase (TPI) performs the 5th step in glycolysis, operates near the limit of diffusion, and is involved in "moonlighting" functions. Its dimer was found singly phosphorylated at Ser20 (pSer20) in human cells, with this post-translational modification (PTM) showing context-dependent stoichiometry and loss under oxidative stress. We generated synthetic pSer20 proteoforms using cell-free protein synthesis that showed enhanced TPI activity by 4-fold relative to unmodified TPI. Molecular dynamics simulations show that the phosphorylation enables a channel to form that shuttles substrate into the active site. Refolding, kinetic, and crystallographic analyses of point mutants including S20E/G/Q indicate that hetero-dimerization and subunit asymmetry are key features of TPI. Moreover, characterization of an endogenous human TPI tetramer also implicates tetramerization in enzymatic regulation. S20 is highly conserved across eukaryotic TPI, yet most prokaryotes contain E/D at this site, suggesting that phosphorylation of human TPI evolved a new switch to optionally boost an already fast enzyme. Overall, complete characterization of TPI shows how endogenous proteoform discovery can prioritize functional versus bystander PTMs.
- 11 August 2022
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 17 (10) , 2769-2780
Revving an Engine of Human Metabolism: Activity Enhancement of Triosephosphate Isomerase via Hemi-Phosphorylation
Triosephosphate isomerase (TPI) performs the 5th step in glycolysis, operates near the limit of diffusion, and is involved in "moonlighting" functions. Its dimer was found singly phosphorylated at Ser20 (pSer20) in human cells, with this post-translational modification (PTM) showing context-dependent stoichiometry and loss under oxidative stress. We generated synthetic pSer20 proteoforms using cell-free protein synthesis that showed enhanced TPI activity by 4-fold relative to unmodified TPI. Molecular dynamics simulations show that the phosphorylation enables a channel to form that shuttles substrate into the active site. Refolding, kinetic, and crystallographic analyses of point mutants including S20E/G/Q indicate that hetero-dimerization and subunit asymmetry are key features of TPI. Moreover, characterization of an endogenous human TPI tetramer also implicates tetramerization in enzymatic regulation. S20 is highly conserved across eukaryotic TPI, yet most prokaryotes contain E/D at this site, suggesting that phosphorylation of human TPI evolved a new switch to optionally boost an already fast enzyme. Overall, complete characterization of TPI shows how endogenous proteoform discovery can prioritize functional versus bystander PTMs.
- 27 March 2021
- Published by Elsevier in International Journal of Mass Spectrometry
- Vol. 465
Reassembling protein complexes after controlled disassembly by top-down mass spectrometry in native mode
- 27 March 2021
- Published by Elsevier in International Journal of Mass Spectrometry
- Vol. 465
Reassembling protein complexes after controlled disassembly by top-down mass spectrometry in native mode
- 15 February 2021
- Published by Springer Nature in Nature Methods
- Vol. 18 (3) , 303-308
Decoding the protein composition of whole nucleosomes with Nuc-MS
Current proteomic approaches disassemble and digest nucleosome particles, blurring readouts of the ‘histone code’. To preserve nucleosome-level information, we developed Nuc-MS, which displays the landscape of histone variants and their post-translational modifications (PTMs) in a single mass spectrum. Combined with immunoprecipitation, Nuc-MS quantified nucleosome co-occupancy of histone H3.3 with variant H2A.Z (sixfold over bulk) and the co-occurrence of oncogenic H3.3K27M with euchromatic marks (for example, a >15-fold enrichment of dimethylated H3K79me2). Nuc-MS is highly concordant with chromatin immunoprecipitation-sequencing (ChIP-seq) and offers a new readout of nucleosome-level biology.
- 15 February 2021
- Published by Springer Nature in Nature Methods
- Vol. 18 (3) , 303-308
Decoding the protein composition of whole nucleosomes with Nuc-MS
Current proteomic approaches disassemble and digest nucleosome particles, blurring readouts of the ‘histone code’. To preserve nucleosome-level information, we developed Nuc-MS, which displays the landscape of histone variants and their post-translational modifications (PTMs) in a single mass spectrum. Combined with immunoprecipitation, Nuc-MS quantified nucleosome co-occupancy of histone H3.3 with variant H2A.Z (sixfold over bulk) and the co-occurrence of oncogenic H3.3K27M with euchromatic marks (for example, a >15-fold enrichment of dimethylated H3K79me2). Nuc-MS is highly concordant with chromatin immunoprecipitation-sequencing (ChIP-seq) and offers a new readout of nucleosome-level biology.
- Open Access
- 15 February 2021
- Published by Springer Nature in Research Square
Protocol for Decoding the Protein Composition of Whole Nucleosomes with Nuc-MS: Sample Preparation, Data Acquisition and Analysis
The disassembly and digestion of nucleosome particles in current proteomics approaches forfeits correlations among histones and blurs nucleosome-level information. We developed Nuc-MS which analyzes whole nucleosomes and displays their histone modifications and variants in a single mass spectrum. In this protocol, we provide step-by-step instructions for preparation of mononucleosomes for mass spectrometry (MS) analysis, and parameter sets for Nuc-MS data acquisition and data analysis.
- 15 February 2021
- Published by Springer Nature in Research Square
Open AccessProtocol for Decoding the Protein Composition of Whole Nucleosomes with Nuc-MS: Sample Preparation, Data Acquisition and Analysis
The disassembly and digestion of nucleosome particles in current proteomics approaches forfeits correlations among histones and blurs nucleosome-level information. We developed Nuc-MS which analyzes whole nucleosomes and displays their histone modifications and variants in a single mass spectrum. In this protocol, we provide step-by-step instructions for preparation of mononucleosomes for mass spectrometry (MS) analysis, and parameter sets for Nuc-MS data acquisition and data analysis.
- Open Access
Separation and Characterization of Endogenous Nucleosomes by Native Capillary Zone Electrophoresis – Top-Down Mass Spectrometry (nCZE-TDMS)
We report a novel platform (native capillary zone electrophoresis – top-down mass spectrometry; nCZE-TDMS) for the separation and characterization of whole nucleosomes, their histone subunits, and PTMs. As the repeating unit of chromatin, mononucleosomes (Nucs) are a ~200 kDa complex of DNA and histone proteins involved in the regulation of key cellular processes central to human health and disease. Unraveling the covalent modification landscape of histones and their defined stoichiometries within Nucs helps to explain epigenetic regulatory mechanisms. In nCZE-TDMS, online Nuc separation is followed by a three-tier tandem MS approach that measures the intact mass of Nucs, ejects and detects the constituent histones, and fragments to sequence the histone. The new platform was optimized with synthetic Nucs to reduce both sample requirements and cost significantly compared to direct infusion. Limits of detection were in the low attomole range, with linearity over ~three orders of magnitude. The nCZE-TDMS platform was applied to endogenous Nucs from two cell lines distinguished by overexpression or knockout of histone methyltransferase NSD2/MMSET, where analysis of constituent histones revealed changes in histone abundances over the course of the CZE separation. We are confident the nCZE-TDMS platform will help advance nucleosome-level research in the fields of chromatin and epigenetics.
Open AccessSeparation and Characterization of Endogenous Nucleosomes by Native Capillary Zone Electrophoresis – Top-Down Mass Spectrometry (nCZE-TDMS)
We report a novel platform (native capillary zone electrophoresis – top-down mass spectrometry; nCZE-TDMS) for the separation and characterization of whole nucleosomes, their histone subunits, and PTMs. As the repeating unit of chromatin, mononucleosomes (Nucs) are a ~200 kDa complex of DNA and histone proteins involved in the regulation of key cellular processes central to human health and disease. Unraveling the covalent modification landscape of histones and their defined stoichiometries within Nucs helps to explain epigenetic regulatory mechanisms. In nCZE-TDMS, online Nuc separation is followed by a three-tier tandem MS approach that measures the intact mass of Nucs, ejects and detects the constituent histones, and fragments to sequence the histone. The new platform was optimized with synthetic Nucs to reduce both sample requirements and cost significantly compared to direct infusion. Limits of detection were in the low attomole range, with linearity over ~three orders of magnitude. The nCZE-TDMS platform was applied to endogenous Nucs from two cell lines distinguished by overexpression or knockout of histone methyltransferase NSD2/MMSET, where analysis of constituent histones revealed changes in histone abundances over the course of the CZE separation. We are confident the nCZE-TDMS platform will help advance nucleosome-level research in the fields of chromatin and epigenetics.